Income Statement
CADRENAL THERAPEUTICS, INC.
CVKD
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY |
|---|---|---|---|---|
|
Revenue
|
- | - | - | - |
|
Cost of Revenue
|
- | - | - | - |
|
Gross Profit
|
- | - | - | - |
|
Operating Expenses
|
13.46 | 10.96 | 7.63 | 2.70 |
|
Research & Development
|
4.10 | 4.21 | 4.08 | 0.39 |
|
Selling, General & Administrative
|
9.35 | 6.75 | 3.55 | 2.31 |
|
Other Operating Expenses
|
- | - | - | - |
|
Operating Income
|
-13.46 | -10.96 | -7.63 | -2.70 |
|
Non-Operating Income
|
0.22 | 0.31 | -0.72 | - |
|
Interest Income
|
0.22 | 0.31 | 0.25 | - |
|
Interest Expense
|
- | - | - | 0.04 |
|
Other Non-Op Income / Expense
|
- | - | - | - |
|
Income Before Tax
|
- | - | - | - |
|
Income Tax Expense
|
- | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - |
|
Net Income
|
-13.24 | -10.65 | -8.36 | -6.71 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY |
|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - |
|
EBITDA
|
-13.46 | -10.96 | -7.63 | -2.70 |
|
Earnings Per Share (Basic)
|
-6.64 | -8.73 | -0.62 | -0.85 |
|
Diluted EPS
|
-6.64 | -8.73 | -0.62 | -0.85 |
|
Weighted Average Shares
|
1.99 | 1.22 | 13.49 | 7.89 |
|
Diluted Weighted Avg Shares
|
1.99 | 1.22 | 13.49 | - |
|
Comprehensive Income
|
- | - | - | - |